EPHX2 and atherosclerosis: In contrast, elevating the levels of endogenous CYP products by removing (sEH knockout mice) or inhibiting soluble epoxide hydrolase (sEH-1) has been shown to reduce neointima formation [28], atherosclerosis and abdominal aortic aneurysm development, dyslipidaemia in hyperlipidaemic mice [29], and reduce hypertension [30] and diabetes [31] in different mouse models.